Submission of BRSR for FY 2025-26.

August 3, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Business Responsibility & Sustainability Report for FY 2025-26 Pursuant to Regulations 34 (2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Business Responsibility & Sustainability Report of the Company for the Financial Year 2025-26. Please take the information on record. Thanking you, Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Encl: as above. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com Business Responsibility & Sustainability Report Section A GENERAL DISCLOSURES I - DETAILS OF LISTED ENTITIES 1. Corporate Identity Number (CIN) of the Listed Entity L24239TG1986PLC015190 2. Name of the Listed Entity Aurobindo Pharma Limited 3. Year of incorporation 1986 4. Registered office address Plot no.2, Maithrivihar, Behind Maithrivanam, Ameerpet, Hyderabad - 500038, Telangana, India 5. Corporate address Galaxy, Floor 22-24; Plot No 1, Sy No 83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad - 500032, Telangana, India 6. E-mail info@aurobindo.com 7. Telephone 040-66721200 8. Website www.aurobindo.com 9. Financial year for which reporting is being done 2025-26 10. Name of the Stock Exchange(s) where shares are listed BSE Limited, National Stock Exchange of India Limited 11. Paid-up Capital INR 58,08,01,623 12. Name and contact details (telephone, email address) of the Mr. B. Adi Reddy, person who may be contacted in case of any queries on the Company Secretary & Compliance Officer BRSR report Phone: +91 40 6672 5333 Email: cs@aurobindo.com 13. Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on The disclosure under BRSR is on consolidated basis, a consolidated basis (i.e. for the entity and all the entities unless otherwise stated which form a part of its consolidated financial statements, taken together). 14. Name of assurance provider M/s. Sharp & Tannan Associates 15. Type of assurance obtained Reasonable Assurance II – PRODUCTS AND SERVICES 16. Details of business activities (accounting for 90% of the Turnover) Sl. % of Turnover of Description of Main Activity Description of Business Activity No the entity 1 Manufacturing Chemical and chemical products, pharmaceuticals, medicinal 100 % chemical and botanical products 17. Products/Services sold by the entity (accounting for 90% of the Entity’s Turnover) Sl. % of total Turnover Product/Service NIC Code No contributed 1 Development, Manufacture and Sale of Active Pharma Ingredients and 21009 100% Formulations III - OPERATIONS 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants* Number of offices Total National 28 3 31 International 5 52 57 * Note: 31 manufacturing facilities out of 33 are under commercial operations 19. Markets served by the entity: A. Number of locations: Locations Number National (No. of States and Union Territories) 28 States; 7 Union Territories International (No. of Countries) 151 countries B. What is the contribution of exports as a percentage of the total turnover of the entity? C. A brief on types of customers Generic customers, Major pharma customers, Institutional customers and Health care professionals IV – EMPLOYEES 20. Details as at the end of Financial Year A. Employees and workers (including differently abled): Sl. Male Female Particulars Total No No. % No. % Employees 1 Permanent 29,209 26,311 90% 2,898 10% 2 Other than Permanent - - - - - Total employees 29,209 26,311 90% 2,898 10% Workers 1 Permanent - - - - - 2 Other than Permanent 17,246 13,819 80% 3,427 20% Total workers 17,246 13,819 80% 3,427 20% B. Differently abled Employees and workers: Sl. Male Female Particulars Total No No. % No. % Employees 1 Permanent 3 3 100% - - 2 Other than Permanent - - - - - 3 Total employees 3 3 100% - - Workers 4 Permanent - - - - - 5 Other than Permanent - - - - - 6 Total workers - - - - - 21. Participation/Inclusion/Representation of women No. and percentage of Females Particulars Total No. % Board of Directors 9 1 11% Key Management Personnel 4 - - 22. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years) FY 2026 FY 2025 FY 2024 Particulars Male Female Total Male Female Total Male Female Total Permanent Employees 15% 19% 15% 13% 19% 13% 15% 28% 16% Permanent Workers - - - - - - - - - V – HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES) 23. Names of holding / subsidiary / associate companies / joint ventures % of Does the entity indicated Indicate whether shares at column A, participate in Sl. Name of the holding /subsidiary / associate holding/ Subsidiary/ held by the Business Responsibility No companies / joint ventures Associate/ Joint listed initiatives of the listed Venture entity entity? (Yes/No) 1 Helix Healthcare B.V. Subsidiary 100% Yes 2 Agile Pharma B.V. Subsidiary 100% Yes 3 Aurex B.V. (Merged with Aurobindo Pharma B.V. Subsidiary 100% Yes w.e.f. 1st April, 2024) 4 Milpharm Limited Subsidiary 100% Yes 5 Aurobindo Pharma (Malta) Ltd Subsidiary 100% Yes 6 APL Swift Services (Malta) Ltd Subsidiary 100% Yes 7 Aurobindo Pharma (Romania) s.r.l Subsidiary 100% Yes 8 Pharmacin B.V. (formerly known as Aurex B.V.) Subsidiary 100% Yes 9 Aurovitas Pharma Polska Subsidiary 100% Yes 10 Generis Farmaceutica S.A. Subsidiary 100% Yes 11 Generis Phar, Unipessoal Lda Subsidiary 100% Yes 12 Aurobindo Pharma (Italia) S.r.l Subsidiary 100% Yes 13 Arrow Generiques SAS Subsidiary 100% Yes 14 1980 Puren Pharma GmbH (formerly Actavis Subsidiary 100% Yes Management GmbH), Germany 15 Puren Pharma GmbH & Co., KG (formerly Actavis Subsidiary 100% Yes Deutschland GmbH & Co., KG) 16 Aurovitas Spain SA (formerly Actavis Spain S.A) Subsidiary 100% Yes 17 Aurobindo Pharma B.V. (formerly known as Subsidiary 100% Yes Actavis B.V.) 18 Aurovitas Spol s.r.o (formerly Apotex (CR) Spol Subsidiary 100% Yes s.r.o.) 19 Apotex Europe B.V. Subsidiary 100% Yes 20 Aurovitas Nederland B.V (formerly Apotex Subsidiary 100% Yes Nederland B.V.) 21 Sameko Farma B.V. Subsidiary 100% Yes 22 Leidapharm B.V. Subsidiary 100% Yes 23 Marel B.V. Subsidiary 100% Yes 24 Pharma Dossier B.V. Subsidiary 100% Yes 25 Aurobindo NV/SA Subsidiary 100% Yes 26 CuraTeQ Biologics s.r.o. Subsidiary 100% Yes 27 Eugia Pharma B.V. Subsidiary 100% Yes 28 Eugia Pharma (Malta) Limited Subsidiary 100% Yes 29 Eugia (UK) Limited Subsidiary 100% Yes 30 Ace Laboratories Limited (w.e.f 28 June 2024) Subsidiary 100% Yes 31 APL Pharma Thai Limited Subsidiary 97.90% Yes 32 Aurobindo Pharma Industria Farmaceutica Ltd Subsidiary 99.97% Yes 33 Aurobindo Pharma Produtos Farmaceuticos Subsidiary 100% Yes Limitada 34 All Pharma (Shanghai) Trading Co Ltd Subsidiary 100% Yes 35 Auro Pharma Inc. Subsidiary 100% Yes % of Does the entity indicated Indicate whether shares at column A, participate in Sl. Name of the holding /subsidiary / associate holding/ Subsidiary/ held by the Business Responsibility No companies / joint ventures Associate/ Joint listed initiatives of the listed Venture entity entity? (Yes/No) 36 Aurobindo Pharma (Pty) Ltd Subsidiary 100% Yes 37 Purple Bellflower, South Africa Subsidiary 100% Yes (w.e.f. 30th April, 2024) 38 Aurobindo Pharma Japan K.K. [Showing first 8,000 characters — download PDF for full document]